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Abstract
Background
Polycystic kidney disease (PKD) is the most frequent hereditary cause of chronic kidney dis-
ease. Peritoneal dialysis (PD) is often avoided for patients with PKD because of the sus-
pected risk of mechanical and infectious complications. Only a few studies have analyzed
the outcome of PKD patients on PD with sometimes conflicting results. The purpose of this
meta-analysis was to investigate outcomes of patients with PKD treated by PD.
Methods
A systematic review and meta-analysis were performed examining all studies which
included “Polycystic kidney disease” and “Peritoneal dialysis” in their titles, excluding com-
mentaries, letters to the authors and abstracts. PubMed, Embase, Google scholar and Sco-
pus were searched to December 31st 2017. The primary outcome was overall patient
survival. Additional outcomes were PD technique survival, incidence of peritonitis and inci-
dence of abdominal wall hernia.
Results
9 studies published between 1998 and 2016 were included for analysis with a total of 7,197
patients including 882 PKD patients. Overall survival of PKD patients was found to be better
compared to non-PKD patients (HR = 0.70 [95% CI, 0.54–0.92]). There were no statistical
differences between PKD and non-PKD patients in terms of peritonitis (OR = 0.86 [95% CI,
0.66–1.12]) and technical survival (HR = 0.98 [95% CI, 0.83–1.16]). There was an increased
risk of hernia in PKD patients (OR = 2.28 [95% CI, 1.26–4.12]).
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Conclusions
PKD is associated with a better global survival, an increased risk of abdominal hernia, but
no differences in peritonitis rate or technical survival were found. PD is a safe dialysis modal-
ity for PKD patients. Properly designed controlled studies are needed to determine whether
all PKD patients are eligible for PD or whether some specific criteria should be determined.
Introduction
Polycystic kidney disease (PKD) is the most frequent hereditary cause of chronic kidney dis-
ease. [1,2]. Peritoneal dialysis (PD) is often avoided for PKD patients when it comes to the
choice of renal replacement therapy. Indeed, enlarged kidneys and liver may reduce the perito-
neal extensibility, leading to increased intraperitoneal pressure [3,4]. Higher prevalence of
abdominal wall hernia, leaks, and diverticulitis-related peritonitis have been reported with PD
administration in PKD patients [5]. These complications may directly impact on PD technique
survival and on patients’ outcomes. However, only a small number of studies have been
designed to analyze the incidence of these events and their relation with PD technical survival
or global patient survival. The purpose of this review and meta-analysis was to investigate the
outcome of patients with PKD treated by PD.
Methods
Study design
This systematic review with meta-analysis was conducted according to a prespecified protocol
and was reported using Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [6].
Search strategy and selection criteria
A bibliographic search was performed from the inception to December 31st 2017 in the follow-
ing databases: Pubmed, Embase, Google scholar and Scopus. We also screened references of
included articles to identify other potential studies. The search strategy, on the article title, was
as follows: "polycystic kidney"[title] OR "polycystic kidney disease"[title] OR ADPKD[title] or
"autosomic dominant polycystic kidney disease"[title]) AND "peritoneal dialysis"[title]. One
author (VD) performed the full search strategy and removed duplicates.
Study selection and data extraction
After eliminating duplicates, two authors (VD, MS) independently reviewed the titles and
abstracts of all articles. Disagreements were resolved by consensus. Agreement between the
two authors was assessed using the Kappa coefficient. After agreement, the full text of all arti-
cles designated for inclusion was obtained. Two authors (VD, MS) checked to ensure that all
articles met the criteria for inclusion in this analysis, and then independently extracted the
data into a standardized form. Extracted data were: study design, country, number of subject
included, percentage of male, age, comorbidity (Charlson index, diabetes mellitus and hyper-
tension), percentage of patients treated by automated peritoneal dialysis, transfer to hemodial-
ysis, access to kidney transplantation, dialysis adequacy, hemoglobinemia, albuminemia,
overall survival, PD technique survival defined as permanent cessation of PD therapy due to
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PD related complications, and occurrence of peritonitis or abdominal hernia. Study authors
were contacted to obtain missing data. Studies were included if they presented at least two of
the following parameters: overall survival, PD technique survival, incidence of peritonitis, and
incidence of abdominal hernia. Studies were excluded if they presented any one or more of the
following criteria: case report, case series, abstracts, commenters or letter to the editor, lan-
guage other than French or English.
Risk-of-Bias assessment
The quality of included studies was assessed independently by two researchers (VD, MS) using
the Newcastle-Ottawa scale (NOS) for cohort studies [7]. The NOS consists of three quality
parameters, namely selection, comparability, and outcome assessment. The NOS assigns a
maximum of four points for selection, two points for comparability and three points for out-
come. NOS scores of7 were considered as high quality studies and 5–6 as moderate quality
[8]. Disagreement was resolved by joint review of the manuscript to reach consensus. Publica-
tion bias was assessed using funnel plots and the Egger’s regression test if there were up to 10
eligible studies included in the meta-analysis [9,10].
Statistical analysis
The primary outcome was overall survival. Secondary outcomes were: 1/ PD technique sur-
vival defined as permanent cessation of PD therapy due to PD related complications, (consid-
ering any other outcome as censored data), 2/ percentage of peritonitis and 3/ frequency of
abdominal hernias. Extracted data were presented as number and percentage for qualitative
variables, and as mean and standard deviation (or median and range) for quantitative vari-
ables. Heterogeneity between studies was assessed using the Cochran Q statistic and I2 test. A
random effects model was used independently of the existence or absence of heterogeneity
between the results of the studies because results of studies with different design and patients’
characteristics were pooled. For time to event outcomes, when hazard ratios (HR) were not
specified, they were estimated according to the information presented in the paper [11]. PKD
and non PKD patients were compared through random effects models weighted by the
inverse-variance method to estimate pooled HR and odds ratios (OR) with 95% confidence
intervals (CIs). Sensitivity analyses were performed. All analyses were performed using R ver-
sion 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Study characteristics
Using the search strategy (Fig 1), we identified 9 eligible studies [12–20] presenting at least two
outcome of interest. The agreement in selection of studies between the reviewers was excellent
(κ = 1). All the studies included in the meta-analysis were considered as high quality studies
(details showed in Table 1). Publication bias, using funnel plot and the Egger’s regression test,
was not assessed as the number of studies included in this meta-analysis was less than 10 stud-
ies [9,10].
General characteristics of the studies included in the meta-analysis are presented in Table 2.
A total of 7,197 patients were included for analysis, including 882 PKD patients. Seven of the 9
studies were retrospective. In two of the 9 studies [14,20], PKD patients were significantly
younger than non PKD.
Clinical characteristics of patients included are summarized in Table 3. Patients did not
differ between the PKD and non PKD groups in terms of hypertension, access to kidney
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transplantation and transfer to hemodialysis. In one of the 9 studies [14], Charlson index was
found to be higher in non PKD patients. Most of the patients were treated by continuous
ambulatory peritoneal dialysis while only Yang et al. reported a higher prevalence of auto-
mated peritoneal dialysis in the PKD group [12].
Biological characteristics of patients included are shown in Table 4. There was no difference
in serum albumin level and dialysis adequacy in term of total weekly Kt/V urea between
PKD and non PKD patients. In two studies [14,17], hemoglobin level was higher in PKD
patients.
Fig 1. Literature search strategy and results.
https://doi.org/10.1371/journal.pone.0196769.g001
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Outcomes
Overall survival. There were 5 studies that reported hazard ratios for PKD and non PKD
patient survival. 6,378 patients from Europe and China were included in the meta-analysis.
PKD status was associated with a better global survival with a Hazard Ratio of 0.70 [95% CI,
0.54–0.92] (Fig 2).
PD technique survival. Seven studies reported hazard ratios for PD technique survival in
both groups, which included a total of 7,046 patients from Europe, China and Taiwan. There
Table 1. Quality of the studies included in the meta-analysis assessed with Newcastle-Ottawa scale (n = 9).
Study, Year Selection Comparability Outcome NOS
Jankowska et al, 2015    9
Janeiro et al, 2015    9
Yang et al, 2015   7
Lobbedez et al, 2010    9
Li et al, 2011   7
Kumar et al, 2008   7
Xie et al, 2016   7
Hadimeri et al, 1998   7
Koc et al, 2016   7
NOS, Newcastle-Ottawa Scale score; the number of stars () corresponds to the number of complete items (maximum 4 items of Selection, 2 items for Comparability and 3
items for Outcome)
https://doi.org/10.1371/journal.pone.0196769.t001
Table 2. General characteristics of the studies included in the meta-analysis (n = 9).
Study, Year Country Study Design n n Mean Age p Male (%) Follow
up
(M)
Adjusted variables
PKD
+
PKD- PKD+ PKD- PKD
+
PKD-
Jankowska
et al, 2015
Poland Prospective cohort 1712 106 1606 62 (55–72) 60 (47–71) 0.04 42.5 53.3 32 Age, sex, diabetes,
hypertension
Janeiro et al,
2015
Spain Prospective matched
cohort
318 106 212 54.28
(±11.92)
53.43
(±16.43)
0.6 60 61.4 21 Age, CIS
Yang et al,
2015
Taiwan Retrospective propensity-
score matched cohort
556 139 417 53.4
(±14.7)
53.8
(±14.7)
0.78 51.8 54.9 32 -
Lobbedez et al,
2010
France Retrospective cohort 4162 344 3818 56.2 (47.1–
67.9)
71.1 (52.4–
80.7)
- 48 59 17 Age, sex, CIS, center,
type of assistance
Li et al, 2011 China Retrospective matched
cohort
126 42 84 57.3
(±12.0)
56.0
(±11.9)
0.6 64.2 46.4 42
Kumar et al,
2008
England Retrospective matched
cohort
112 56 56 50.8
(±11.6)
50.3
(±11.5)
NS 45 45 37
Xie et al, 2016 China Retrospective matched
cohort
60 30 30 52.5
(±11.0)
52.6
(±11.1)
0.962 60 60 27
Hadimeri et al,
1998
Sweden Retrospective cohort 52 26 26 57 (±11) 53 (±14) 0.002 65 73 18
Koc et al, 2016 Turkey Retrospective cohort 99 33 66 35.4
(±13.1)
46 (±16.8) - 39.4 53 150
n, number of subjects; PKD+, Patients with polycystic kidney disease; PKD-, Patients without polycystic kidney disease; M, Months (median); CIS, Charlson Index Score
, p<0.05
https://doi.org/10.1371/journal.pone.0196769.t002
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was no difference between PKD and non PKD groups in terms of PD technique survival
(HR = 0.98 [95% CI, 0.83–1.16]) as shown in Fig 3.
Infectious complications. Seven studies reported odds ratios for the incidence of infec-
tious peritonitis episodes in PKD and non PKD patients treated by PD. 6,767 patients from
Europe, China, Taiwan and Turkey were included in the meta-analysis (Fig 4). There was no
statistical difference in occurrence of infectious peritonitis between PKD and non PKD
patients (OR = 0.86 [95% CI, 0.66–1.12]) as shown in Fig 4.
Abdominal wall hernias. There were 7 studies that reported odds ratios for the incidence
of abdominal wall hernias in PKD and non PKD patients treated by PD, including a total of
2,923 patients from Europe, China, Taiwan and Turkey (Fig 5). PKD patients were found to
have an increased risk of abdominal hernia with an Odds Ratio of 2.28 [95% CI, 1.26–4.12] as
shown in Fig 5.
Table 3. Clinical characteristics of the studies included in the meta-analysis (n = 9).
Outcome
Study, Year Hypertension
(%)
p CIS p APD (%) p Kidney
transplantation
(%)
p Transfer to
hemodialysis
(%)
p
PKD+ PKD- PKD+ PKD- PKD+ PKD- PKD+ PKD- PKD+ PKD-
Jankowska et al, 2015 83 83.9 0.9 - - - 45.3 44.4 0.9 26.4 18.6 0.04 18.9 21.4 0.5
Janeiro et al, 2015 14.7 23 0.21 4.27 (±1.58) 5.27 (±2.5) <0.001 43.4 33.7 0.1 47.2 30.7 0.004 17 20.3 NS
Yang et al, 2015 71.2 73.1 0.66 2.9 (±1.4) 3.0 (±1.4) 0.5 46.8 37.6 0.03 9.4 9.8 0.87 24.5 22.5 0.64
Lobbedez et al, 2010 - - - 3 (3–5) 6 (3–7) - 54.9 34.5 - 52 30 - 32 30 -
Li et al, 2011 95.2 91.7 0.5 4.6 (±1.6) 4.1 (±1.8) 0.1 - - - 9.5 11.9 - 9.5 11.9 -
Kumar et al, 2008 - - - - - - 18.5 17.8 - 39 37 NS 30 25 NS
Xie et al, 2016 100 93.3 0.152 3.3 (±1.1) 3.1 (±1.0) 0.351 - - - 16.7 16.7 1 16.7 20 0.506
Hadimeri et al, 1998 - - - - - 0 0 - 60 41.2 - 25 29.4 -
Koc et al, 2016 - - - - - - 42.4 47 0.36 30.3 16.6 - 30.3 28.8 -
PKD+, Patients with Polycystic Kidney Disease; PKD-, Patients without Polycystic Kidney Disease; CIS, Charlson Index Score; APD, Automated Peritoneal Dialysis
, p<0.05
https://doi.org/10.1371/journal.pone.0196769.t003
Table 4. Biological characteristics of the studies included in the meta-analysis (n = 9).
Study, Year Hemoglobinemia [g/dL] p Albuminemia [g/L] p Kt/V p
PKD+ PKD- PKD+ PKD- PKD+ PKD-
Jankowska et al, 2015 11.4 (±1.5) 11.2 (±1.7) 0.2 37.3 (±6.0) 36.0 (±7.3) 0.1 2.22 (±0.59) 2.33 (±0.71) 0.2
Janeiro et al, 2015 12.63 (±1.44) 11.96 (±1.49) 0.001 - - - 2.68 (±0.65) 2.52 (±0.80) 0.1
Yang et al, 2015 - - - - - - - - -
Lobbedez et al, 2010 - - - - - - - - -
Li et al, 2011 10.4 (±1.7) 9.0 (±1.3) <0.001 32.0 (±5.9) 33.0 (±5.0) 0.4 1.93 (±0.39) 1.99 (±0.37) 0.4
Kumar et al, 2008 11.0 (±1.5) 10.6 (±1.9) NS 39.8 (±3.9) 38.1 (±4.9) NS 2.3 (±0.50) 2.1 (±0.4) NS
Xie et al, 2016 8.1 (±1.6) 8.0 (±1.5) 0.957 41.0 (±5.2) 39.0 (±6.4) 0.182 2.11 (±0.53) 2.08 (±0.56) 0.328
Hadimeri et al, 1998 - - - - - - - - -
Koc et al, 2016 10.7 (±2.0) 10.3 (±2.0) 0.38 38.6 (±5.1) 35.6 (±6.6) 0.03 2.15 (±0.40) 2.03 (±0.60) 0.47
PKD+, Patients with Polycystic Kidney Disease; PKD-, Patients without Polycystic Kidney Disease; Kt/V, Total weekly Kt/V urea
, p<0.05
https://doi.org/10.1371/journal.pone.0196769.t004
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Sensitivity analysis. Because the large weight of the study by Lobbedez et al. among the
included studies might affect the entire analysis, we performed sensitivity analysis to check the
stability of the previous results without including the study by Lobbedez et al. (except for
abdominal wall hernias because this study was not included in analysis for this outcome).
Results are summarized on Table 5. Hazard ratios and Odds ratios showed a great stability
even in the absence of the study by Lobbedez et al. The only observed change in the absence of
the study by Lobbedez et al. was the absence of statistical relevance in the analysis of overall
survival.
Discussion
To our knowledge this is the first meta-analysis designed to study the outcome of PKD patients
on PD. We found that compared to non PKD patients, PKD patients on PD had i) better global
survival, ii) no difference in PD technique survival, iii) no difference in peritonitis rate but
Fig 2. Overall survival of PKD vs non PKD patients treated by peritoneal dialysis. HR, Hazard ratio; CI, Confidence interval.
https://doi.org/10.1371/journal.pone.0196769.g002
Fig 3. Peritoneal dialysis technique survival in PKD vs non PKD patients. HR, Hazard ratio; CI, Confidence interval.
https://doi.org/10.1371/journal.pone.0196769.g003
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increased risk of abdominal hernias. Our results should reassure nephrologists managing PKD
patients regarding the choice of PD as renal replacement therapy.
We found that PKD patients had better survival compared with non PKD patients. This dif-
ference could be explained by lower comorbidities reported in PKD patients: younger age
[14,20], lower Charlson index [14] and higher hemoglobinemia [14,17]. On the other hand,
patients with this hereditary disease are usually diagnosed earlier and monitored with a better
nephrology care and a planned access to PD in optimized conditions. Only one study reports
this factor but it could certainly explain at least in part the good clinical outcome for PD group
in other studies [14].In addition, PKD patients have less comorbidities and may therefore have
better outcome and a relatively lower risk of death or transfer to hemodialysis because of a
Fig 4. Incidence of infectious peritonitis in PKD vs non PKD patients treated by peritoneal dialysis. OR, Odds ratio; CI, Confidence
interval.
https://doi.org/10.1371/journal.pone.0196769.g004
Fig 5. Incidence of hernias in PKD vs non PKD patients treated by peritoneal dialysis. OR, Odds ratio; CI, Confidence interval.
https://doi.org/10.1371/journal.pone.0196769.g005
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higher competing risk of being transplanted (Table 3). Lastly, in one study, diabetes mellitus
was found to be the only predictor of all-cause mortality independently from PKD status [13].
Furthermore, the meta-analysis strategy allowed us to include 7,046 patients for the analysis
of PD technique survival. PD technique survival did not differ according to PKD status. More-
over, there were no statistical difference between PKD and non PKD patients in terms of
access to kidney transplantation or transfer to hemodialysis. Koc et al. reported that causes of
death and transfer to hemodialysis were not different between PKD and non PKD patients
(p = 0.35 and 0.36, respectively) [16]. In the study of Kumar et al, in multivariate analysis [18],
hypoalbuminemia at initiation of PD was found to be the main risk factor for PD therapy ces-
sation independently from PKD status.
Previous reports have suggested an increased incidence of mechanical complications in
PKD patients treated with PD, such as abdominal leak or hernia [5,12]. In these studies,
abdominal hernias were not associated with an increased risk of PD discontinuation. In the
present meta-analysis, we confirm that episodes of abdominal hernia appeared statistically
more often in PKD patients treated with PD. However, abdominal wall complications have
been found to be more frequent in PKD patients at all stages of kidney disease including before
end stage renal disease. As a consequence, it is likely that hernias may not be directly related
to increased intraperitoneal pressure but may be related to collagen defects and thus be
observed in PKD patients treated with other renal replacement therapies [21]. Increased risk
of abdominal hernias was not associated with a decrease in technique survival. This suggests
that for these patients, the therapeutic intervention such as reducing intraabdominal pressure
(reduced volume infused of peritoneal solution or using automated peritoneal dialysis) is suc-
cessful for maintaining them on PD therapy. In addition, studies included in this meta-analysis
did not show any difference in term of fluid leak episode incidence [13,14,18,20].
Some reports indicate that PKD may be associated with an increased risk of diverticulitis,
leading to greater risk of peritoneal infection in patients treated with PD [5]. In the present
meta-analysis, including 6,767 patients, we found that PKD was not associated with a higher
risk of occurrence of peritoneal infection. Furthermore, incidence of peritonitis episode
requiring catheter removal did not differ between groups in Kumar et al. and Xie et al. (25% in
PKD group vs 21% in non PKD group and 6,7% in PKD group vs 3,3% in non PKD group
respectively) [18,19]. Staphylococcus spp was the main causative micro-organism in both
groups while gram-negative organisms incidence did not differ between PKD and non PKD
patients [14,15,17,18,19].
PD treatment offers numerous advantages [22,23], however only 7 to 10% of end-stage
renal disease patients are treated with PD [2]. This reflects, at least in part, the clinicians’ fear
of technical failure [24]. PKD patients are probably more concerned by this issue, because of
the common misconception that these patients will develop infectious and mechanical compli-
cations if treated with PD, due to increased intraperitoneal pressure and a higher incidence of
Table 5. Sensitivity analysis for overall survival, PD technique survival and infectious complications with or without Lobbedez et al. study.
Hazard ratio or Odds
Ratio
Confidence interval Hazard ratio or Odds Ratio w/o Lobbedez
et al.
Confidence interval w/o Lobbedez
et al.
Overall survival HR = 0.70 0.54–0.92 HR = 0.74 0.5–1.09
PD technique survival HR = 0.98 0.83–1.16 HR = 1.00 0.79–1.27
Infectious
complications
OR = 0.86 0.66–1.12 OR = 0.87 0.59–1.28
w/o, without; HR, Hazard ratio; OR, Odds ratio
https://doi.org/10.1371/journal.pone.0196769.t005
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diverticulitis. Our results suggest that PD is a safe renal replacement modality for PKD
patients. To the best of our knowledge, there is no available study designed to assess the impact
of different PD modalities (continuous ambulatory peritoneal dialysis or automated peritoneal
dialysis) on PKD patients’ outcomes.
First limitation of our study is related to the small number of publications on this subject.
Additionally, all the studies included in the meta-analysis are retrospective or registry based
studies. Indeed, there is no randomized clinical trial available on this subject. Therefore, a
potential selection bias may limit the relevance of our conclusions for the entire PKD popula-
tion. However, we collected all the study available (ie 9) and a total of 7,197 patients across the
9 studies (n = 2,923 to 7,046 patients for each outcome). This was a sufficient prerequisite to
perform a meta-analysis. Another limitation is related to the relative importance of the study
by Lobbedez et al. among the included studies due to the large number of patients included
(n = 4162) accounting for almost half of the total population and Furthermore the design of
the Lobbedez study, was different it was the only one including survival analysis after exclusion
of the diabetic patients. However our results show strong stability when analyzed with or with-
out Lobbedez’s study.
In conclusion, this meta-analysis showed that PKD patients treated with PD seem to have
an increased survival and an increased rate of abdominal hernia, without any impact on PD
technique survival. There was no statistical difference in peritonitis rate between PKD and no
PKD patients. Therefore, our data suggest that peritoneal dialysis is a safe modality to treat end
stage renal disease of PKD patients and should be offered to these patients. However, properly
designed controlled studies are needed to determine whether all PKD patients are eligible for
PD or whether some specific criteria should be determined. A particular attention should be
given to the impact of total kidney volume and liver size in the feasibility of PD.
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